The All-Products Clause

A payer usually sells more than one thing. Behind a single brand there may be an employer-sponsored product, a narrow-network product, an exchange product, a Medicare Advantage plan, a Medicaid managed care plan, and arrangements the payer administers for someone else. Each of those has a different enrolled population, different utilization, different administrative rules, and — from the practice's side — a different economics.

An all-products clause removes the practice's ability to choose between them. Accept one and you have accepted the set. The clause does not usually change the rate; that is exactly the problem. The rate was worked out against whichever book of business the negotiation was really about, and the clause extends it to books that were never in the analysis.

The plain version

Participation in any product requires participation in all products the payer currently offers. Visible, and at least it can be argued about.

The future-products version

Extends to products the payer introduces later, sometimes with automatic inclusion and no separate signature. This is the limb worth reading hardest, because it commits the practice to terms that do not yet exist.

The affiliate version

Reaches products of the payer's affiliates, subsidiaries, or entities it acquires. Whether that is what the agreement says depends entirely on how the definitions section defines the counterparty.

The assembled version

No single clause says it. A broad definition of the payer, a participation clause referring to “the products”, and an exhibit that lists them combine to the same effect. This is the common case, and it is why searching the document for the phrase finds nothing.

This is the part most likely to be missed, because it is not in the negotiated text at all. Where one of the bundled products is a Medicare Advantage plan or a Medicaid managed care plan, the downstream contract has to contain provisions that federal regulation requires. They are not concessions the payer extracted; they are terms neither party can leave out.

Medicare Advantage

42 CFR 422.504(i) (opens in a new tab) requires an MA organization's contracts with first tier, downstream and related entities to contain a specific set of provisions. Among them: arrangements prohibiting providers from holding an enrollee liable for payment of fees that are the MA organization's obligation; a requirement that anything performed under the contract be consistent with the MA organization's own obligations; and, where activities are delegated, terms specifying the delegated activities and reporting responsibilities, providing for revocation or other remedies for unsatisfactory performance, requiring ongoing monitoring, addressing credentialing review, and requiring compliance with all applicable Medicare laws, regulations and CMS instructions.

Medicaid managed care

42 CFR 438.230 (opens in a new tab) works the same way. The managed care entity retains “ultimate responsibility for adhering to and otherwise fully complying with all terms and conditions of its contract with the State,” and each subcontract must identify the delegated activities with remedies including revocation, require compliance with all applicable Medicaid laws and regulations including subregulatory guidance, and preserve inspection and audit rights for the State, CMS, the HHS Inspector General and the Comptroller General over the subcontractor's records, systems and facilities — for a period that runs from the end of the contract period or the completion of an audit, whichever is later.

None of that is a reason to refuse a government product line. Practices participate in these programs deliberately and successfully. It is a reason to know that the decision is being made — because the obligations attach on signature whether or not anyone read them, and a records-retention or audit-access obligation is not something a practice can retrofit after a request arrives.

Searching an agreement for “all products” is the least effective way to find one. The effect is usually distributed across four places, none of which is startling in isolation.

1. 01

   The definitions

   How is the counterparty defined? A definition reaching affiliates, subsidiaries, successors and entities under common control does more scope work than the participation clause does. How are “Product”, “Plan” and “Benefit Program” defined, and are they defined by reference to a list that can change?
2. 02

   The participation or scope clause

   Does the practice agree to participate in “the Products” — plural and defined elsewhere — or in named ones? The difference between a definite list and a defined term is the whole question.
3. 03

   The exhibits

   Products and rates usually live in attachments. Check whether each product has its own rate exhibit or whether one exhibit is stated to apply to all of them, and whether the exhibits can be replaced without a new signature — which is where amendment by notice meets this clause and makes it larger.
4. 04

   Any future-products language

   Look for products “now or hereafter offered”, automatic inclusion on launch, or a right to add a product by notice. This is the limb that converts a bounded agreement into an open one.

What a payer will agree to is specific to the payer, the market, and the practice, and this article makes no claim about any of that. What is worth knowing is the shape of the requests, because a request framed as a structural clarification is a different conversation from a request framed as an objection.

• Product-specific rate exhibits. Even where the products stay bundled, separating the rate exhibits makes each one visible and gives every later negotiation something to move.
• A named carve-out. Exclusion of a specific product type, rather than a general right to opt out of anything.
• Notice and an election for future products. Not a veto — a defined window in which to decline a product introduced later, so the open-ended limb becomes a series of decisions rather than one.
• Clarity on affiliates. Whether the products of entities the payer acquires are included, and whether that is stated or left to a definition.
• The provider manual's status. Because a bundled product usually brings its own manual, and whether the manual is incorporated into the contract decides how much of the arrangement is not in the agreement at all.

• One rate analysis, several product lines. The modeling was done for the product the practice wanted. Nothing was modeled for the rest, and the aggregate result only becomes visible in the payment variance months later.
• A product line appears that nobody signed for. The future-products limb worked as written. The first sign is usually patients arriving under a plan name the practice does not recognize.
• A government product line's obligations discovered on demand. The audit-access and records-retention terms were always in the contract because regulation required them. The practice meets them when a request arrives rather than when it signed.
• Termination is all-or-nothing too. A practice that wants out of one product often finds the bundling runs in both directions — which is a question to ask of the termination clause while reading the participation clause, not afterwards.
• The contract inventory records one agreement. It is one signature and several economic relationships, and a register that shows a single row cannot support a renegotiation of any of them.